Age dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction - a multicenter retrospective observational study of young versus old patients.

ABSTRACT:

Objectives

To provide evidence for age-dependent use of neoadjuvant treatment by clinical comparisons of young (lower quartile, <56.6 y) versus old (upper quartile, >71.3 y) esophageal and esophagogastric-junction adenocarcinoma (EAC) patients.

Background

Neoadjuvant treatment is the standard of care for locally advanced and node-positive EAC. However, the effect of age on oncological outcomes is disputable as they are underrepresented in treatment defining randomized controlled trials.

Methods

Patients with EAC undergoing esophagectomy between 2001 and 2022 were retrospectively analyzed from three centers. Patients having distant metastases or clinical UICC-Stage I were excluded. Cox proportional hazards regression was used to identify the variables associated with s

SUBMITTER: Rompen IF 

PROVIDER: S-EPMC10720874 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature